Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of favezelimab + pembrolizumab versus standard therapy in previously treated PD-L1-positive metastatic colorectal cancer
MOH_2021-08-08_010133Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of favezelimab and pembrolizumab in colorectal cancer (CRC) (2 arms), sponsored by Merck & Co. Started Aug 2021; status: active, not recruiting.
02
Drugs
favezelimabpembrolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on MOH_2021-08-08_010133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-08_010133.